Literature DB >> 25724413

Combination of exosomes and circulating microRNAs may serve as a promising tumor marker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats.

Wei-hui Liu1, Li-na Ren, Xing Wang, Tao Wang, Ning Zhang, Yuan Gao, Hao Luo, Nalu Navarro-Alvarez, Li-jun Tang.   

Abstract

PURPOSE: Due to unsatisfying prognosis of AFP for hepatocellular carcinoma (HCC), we aim to evaluate the prognostic value of combination of exosomes and miRNAs in detecting HCC.
METHODS: HCC was induced with diethylnitrosamine in rats and using a scoring system based on histological examination six different stages (normal liver, degeneration, fibrosis, cirrhosis, early HCC and late HCC) were identified in the development of HCC. The expression levels of AFP, exosomes and miRNAs (miRNA-10b, miRNA-21, miRNA-122 and miRNA-200a) were detected in both tissue and blood samples from those six stages. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the power of each parameter and their different combinations in diagnosing HCC or cirrhosis.
RESULTS: A change in the expression of both exosomes and miRNAs was observed during cirrhosis, which in contrast with AFP starts showing up until the early HCC stage. Interestingly, the expressions of exosomes and the selected four miRNAs at early HCC stage obtained more remarkably alterations than the level of AFP (P < 0.05). On correlation analysis, four selected miRNAs had a significant closer relationship with exosomes when compared with AFP. The different combinations of AFP, exosomes, serous miRNAs and exosomal miRNAs had stronger power in predicting HCC than AFP (area under the curve of ROC, 0.943 vs 0.826).
CONCLUSION: To conclude, the combination of circulating miRNAs and exosomes might serve as promising biomarkers for non-virus infected HCC screening and cirrhosis discrimination.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25724413     DOI: 10.1007/s00432-015-1943-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

1.  Comparison of serum exosome isolation methods for microRNA profiling.

Authors:  Kadri Rekker; Merli Saare; Anne Mari Roost; Anna-Liisa Kubo; Natasa Zarovni; Antonio Chiesi; Andres Salumets; Maire Peters
Journal:  Clin Biochem       Date:  2013-10-29       Impact factor: 3.281

2.  MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma.

Authors:  Changzheng Liu; Jia Yu; Shuangni Yu; Robert M Lavker; Lei Cai; Wei Liu; Kegong Yang; Xiaodong He; Songsen Chen
Journal:  J Hepatol       Date:  2010-04-04       Impact factor: 25.083

3.  Notch is the key factor in the process of fetal liver stem/progenitor cells differentiation into hepatocytes.

Authors:  Tao Wang; Nan You; Kaishan Tao; Xing Wang; Ge Zhao; Ning Xia; Nanlin Li; Lijun Tang; Weihui Liu; Kefeng Dou
Journal:  Dev Growth Differ       Date:  2012-06-10       Impact factor: 2.053

Review 4.  The cancer stem cell: premises, promises and challenges.

Authors:  Hans Clevers
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways.

Authors:  Longlong Bao; Yan Yan; Can Xu; Weidan Ji; Shuwen Shen; Gaoya Xu; Yong Zeng; Bin Sun; Haihua Qian; Lei Chen; Mengchao Wu; Changqing Su; Jie Chen
Journal:  Cancer Lett       Date:  2013-05-14       Impact factor: 8.679

8.  Notch inhibition promotes fetal liver stem/progenitor cells differentiation into hepatocytes via the inhibition of HNF-1β.

Authors:  Tao Wang; Tao Chen; Hong-Yin Liang; Hong-Tao Yan; Ning Lin; Li-Ye Liu; Hao Luo; Zhu Huang; Nan-Lin Li; Wei-Hui Liu; Li-Jun Tang
Journal:  Cell Tissue Res       Date:  2014-04-17       Impact factor: 5.249

Review 9.  MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?

Authors:  Silvia Giordano; Amedeo Columbano
Journal:  Hepatology       Date:  2012-12-26       Impact factor: 17.425

10.  MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3.

Authors:  Guangxian Xu; Yilin Zhang; Jun Wei; Wei Jia; Zhaohui Ge; Zhaobo Zhang; Xiaoming Liu
Journal:  BMC Cancer       Date:  2013-10-10       Impact factor: 4.430

View more
  28 in total

1.  A novel E1B55kDa-deleted oncolytic adenovirus carrying microRNA-143 exerts specific antitumor efficacy on colorectal cancer cells.

Authors:  Qifeng Luo; Shiva Basnet; Zhenling Dai; Shuping Li; Zhenyu Zhang; Haiyan Ge
Journal:  Am J Transl Res       Date:  2016-09-15       Impact factor: 4.060

Review 2.  The functional role of exosome in hepatocellular carcinoma.

Authors:  Hongyu Liu; Baoguo Li
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-30       Impact factor: 4.553

Review 3.  Exosomes in liver pathology.

Authors:  Keisaku Sato; Fanyin Meng; Shannon Glaser; Gianfranco Alpini
Journal:  J Hepatol       Date:  2016-03-14       Impact factor: 25.083

Review 4.  Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma.

Authors:  Changbiao Li; Xiao Xu
Journal:  Cell Mol Life Sci       Date:  2019-07-12       Impact factor: 9.261

Review 5.  Clinical implications of exosome-derived noncoding RNAs in liver.

Authors:  Zhe Wen Zhou; Wei Zheng; Zheng Xiang; Cun Si Ye; Qiao Qiao Yin; Shou Hao Wang; Cheng An Xu; Wen Hao Wu; Tian Chen Hui; Qing Qing Wu; Ling Yun Zhao; Hong Ying Pan; Ke Yang Xu
Journal:  Lab Invest       Date:  2022-01-10       Impact factor: 5.662

6.  Comparison of the extraction and determination of serum exosome and miRNA in serum and the detection of miR-27a-3p in serum exosome of ALS patients.

Authors:  Qian Xu; Yuying Zhao; Xiaoyan Zhou; Jing Luan; Yazhou Cui; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2018-02

Review 7.  Exosomes as potent regulators of HCC malignancy and potential bio-tools in clinical application.

Authors:  Zhen Qu; Chunping Jiang; Junhua Wu; Yitao Ding
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 8.  Exosomal microRNAs in hepatocellular carcinoma.

Authors:  Chenbin Liu; Han Wu; Yinqi Mao; Wei Chen; Shuying Chen
Journal:  Cancer Cell Int       Date:  2021-05-08       Impact factor: 5.722

Review 9.  Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma.

Authors:  Andrei Sorop; Diana Constantinescu; Florentina Cojocaru; Anca Dinischiotu; Dana Cucu; Simona Olimpia Dima
Journal:  Int J Mol Sci       Date:  2021-05-08       Impact factor: 5.923

Review 10.  Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment.

Authors:  Mengtao Xing; Xinzhi Wang; Robert A Kiken; Ling He; Jian-Ying Zhang
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.